New Parkinson's drug HER-096 passes first safety check in small trial
NCT ID NCT06659562
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety of a new drug called HER-096 for Parkinson's disease. It involved 32 people: healthy volunteers who got a single dose, and Parkinson's patients who received multiple doses over four weeks. The main goal was to check for side effects and how the body handles the drug, not yet to see if it improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HER-096
What this could lead to
If successful, this could pave the way for larger studies testing whether HER-096 can slow or modify Parkinson's disease progression.
What could go wrong
This is a very early Phase 1 safety trial with only 32 people. It is not designed to prove whether the drug works for Parkinson's, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE, IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, Finland, Finland